Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.66 |
| ▸ | RXRB | P28702 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 4/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806827 | 0.94 | RXRA (0.60) | RXRARXRBLMNACYP1A2PTGS1 | |
| SCHEMBL11844142 | 0.94 | RXRA (0.60) | RXRARXRBLMNACYP1A2PTGS1 | |
| SCHEMBL12603773 | 0.94 | APP (0.64) | RXRARXRBLMNACYP1A2PTGS1 | |
| SCHEMBL11855314 | 0.90 | LTA4H (0.60) | RXRARXRBLMNACYP1A2PTGS1 | |
| SCHEMBL13462732 | 0.90 | GSTP1 (0.63) | RXRARXRBLMNACYP1A2PTGS1 | |
| SCHEMBL19382100 | 0.89 | AR (0.59) | RXRARXRBLMNACYP1A2PTGS1 | |
| SCHEMBL10609652 | 0.87 | LMNA (0.75) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL339813 | 0.87 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL27367676 | 0.87 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL11293541 | 0.85 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004022542-A2 | SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | Grünenthal GmbH (DE) | 2004-03-18 | — | — | WO | claimed |
| WO-2024139260-A1 | ALLICIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USES THEREOF | 成都新朝阳作物科学股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240016578-A1 | METHODS FOR ADDITIVELY MANUFACTURING MEDICAL DEVICES USING BIOGLASS FIBER REINFORCED POLYMERS | TU WIEN (AT) | 2024-01-18 | — | — | US | disclosed |
| CN-114716296-B | Efficient halogenation synthesis method of alkyl halide | 润药仁智(北京)科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4272962-A2 | CURABLE COMPOSITION FOR USE IN A HIGH TEMPERATURE PHOTOPOLYMERISATION METHOD ON A LITHOGRAPHY BASIS AND PROCESS FOR THE PREPARATION OF CROSS-LINKED POLYMERS THEREFROM | Align Technology, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116947720-A | Allicin derivative and preparation method and application thereof | 成都新朝阳作物科学股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230210635-A1 | CURABLE COMPOSITION FOR USE IN A HIGH TEMPERATURE LITHOGRAPHY-BASED PHOTOPOLYMERIZATION PROCESS AND METHOD OF PRODUCING CROSSLINKED POLYMERS THEREFROM | ALIGN TECHNOLOGY INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210635-A1 | CURABLE COMPOSITION FOR USE IN A HIGH TEMPERATURE LITHOGRAPHY-BASED PHOTOPOLYMERIZATION PROCESS AND METHOD OF PRODUCING CROSSLINKED POLYMERS THEREFROM | ALIGN TECHNOLOGY INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-5470833-A | Vasodilators, bronchodilators | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| US-5446164-A | Regioselective cyclization of phenethylamide derivative in presence of phosphoric acid halide, reducing formed compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-29 | — | — | US | disclosed |
| US-5444152-A | Vasolidator or bronchodilator | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0617022-A1 | 6,7, dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-09-28 | — | — | EP | disclosed |
| EP-0486745-A1 | Improved solvents for chromogens useful in the manufacture of carbonless copying paper | MONSANTO EUROPE S.A./N.V. (BE) | 1992-05-27 | — | — | EP | disclosed |
| EP-0460679-A2 | Endothelin antagonistic peptide derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0114385-B1 | ELECTRICAL INSULATING OIL AND OIL-FILLED ELECTRICAL APPLIANCES | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1987-08-05 | — | — | EP | disclosed |
| US-4543207-A | ORGANIC ACID ESTERS, AROMATIC ETHERS, ANIMAL OILS, VEGETABLE OILS,AND AROMATIC OLEFINS | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1985-09-24 | — | — | US | disclosed |
| EP-0114385-A2 | Electrical insulating oil and oil-filled electrical appliances | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1984-08-01 | — | — | EP | disclosed |
| US-3968320-A | Dye solvents for pressure-sensitive record material | MONSANTO COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | RXRA 3366/4885RXRB 3716/4885LMNA 1466/4885 |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | RXRA 804/4885RXRB 717/4885LMNA 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.